Expression of activation antigens after pamidronate/IL-2 infusion of patients from cohort B
. | . | αβ T cells . | . | . | NK cells . | . | . | γδ T cells . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose level, IL-2 IU/m2 . | Patient, n . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | ||||||
| 0.25 × 106 | 3 | 3 (−56-71) | 10 (0-15) | 0/3 (0) | 24 (−17-43) | 0 (0-123) | 0/3 (0) | 0 (−23-101) | 163 (−7-375) | 1/3 (33) | ||||||
| 0.5 × 106 | 3 | 33 (−23-95) | 37 (27-86) | 1/3 (33) | 0 (−26-81) | 0 (0-67) | 0/3 (0) | 53 (38-167) | 400 (0-831) | 2/3 (66) | ||||||
| 1 × 106 | 4 | 62 (3-153) | 45 (0-122) | 0/4 (0) | 23 (18-27) | 8 (−38-54) | 0/2 (0) | 183 (82-426) | 322 (0-1253) | 3/4 (75) | ||||||
| 2 × 106 | 3 | 65 (52-98) | 60 (19-121) | 2/3 (66) | 81 (−37-103) | 93 (79-291) | 2/3 (66) | 186 (62-230) | 124 (122-571) | 3/3 (100) | ||||||
. | . | αβ T cells . | . | . | NK cells . | . | . | γδ T cells . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose level, IL-2 IU/m2 . | Patient, n . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | CD69, % mean (range) . | HLA-DR, % mean (range) . | CD69+ HLA-DR, n/patients (%) . | ||||||
| 0.25 × 106 | 3 | 3 (−56-71) | 10 (0-15) | 0/3 (0) | 24 (−17-43) | 0 (0-123) | 0/3 (0) | 0 (−23-101) | 163 (−7-375) | 1/3 (33) | ||||||
| 0.5 × 106 | 3 | 33 (−23-95) | 37 (27-86) | 1/3 (33) | 0 (−26-81) | 0 (0-67) | 0/3 (0) | 53 (38-167) | 400 (0-831) | 2/3 (66) | ||||||
| 1 × 106 | 4 | 62 (3-153) | 45 (0-122) | 0/4 (0) | 23 (18-27) | 8 (−38-54) | 0/2 (0) | 183 (82-426) | 322 (0-1253) | 3/4 (75) | ||||||
| 2 × 106 | 3 | 65 (52-98) | 60 (19-121) | 2/3 (66) | 81 (−37-103) | 93 (79-291) | 2/3 (66) | 186 (62-230) | 124 (122-571) | 3/3 (100) | ||||||
Results represent means of increase of the percentages of positive cells analyzed by double or triple staining (NK cells). CD69 was determined on day 2 or 3 and HLA-DR on day 7 after infusion. For analysis of patients expressing CD69 and HLA-DR, a threshold of 50% positive cells on day 8 was defined.